$MLGO
MicroAlgo Inc. Stock $mlgo

$mlgo Overview Financials Valuation SEC Filings Company Website

2022 Q3 Form 10-Q Financial Statement

#000182912622015804 Filed on August 15, 2022

Income Statement

Concept	2022 Q3	2022 Q2	2022 Q1
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue		$276.4M	$17.96M
YoY Change
Gross Profit	$433.3K	-$23.60K	$5.396M
YoY Change	-229.88%	-89.18%
Gross Profit Margin
Selling, General & Admin		$14.80M	$809.2K
YoY Change
% of Gross Profit			15.0%
Research & Development		$40.20M	$3.203M
YoY Change
% of Gross Profit			59.36%
Depreciation & Amortization		$4.470M	$343.4K
YoY Change
% of Gross Profit			6.36%
Operating Expenses	$100.1K	$90.52K	$167.6K
YoY Change	-70.07%	-58.64%	109.55%
Operating Profit	$333.3K	-$114.1K	$1.177M
YoY Change	-149.89%	-73.88%
Interest Expense	$533.4K	$66.92K	-$6.190K
YoY Change	75023.94%	9325.35%	-79.37%
% of Operating Profit	160.05%		-0.53%
Other Income/Expense, Net	$533.4K	$66.92K	-$277.0K
YoY Change	74602.8%	9378.33%	835.31%
Pretax Income	$433.3K	-$23.60K	-$173.8K
YoY Change	-229.88%	-89.18%	60.46%
Income Tax
% Of Pretax Income
Net Earnings	$433.3K	-$23.60K	-$173.8K
YoY Change	-229.88%	-89.18%	60.46%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	$71.62K	-$3.901K	-$28.73K
COMMON SHARES
Basic Shares Outstanding	6.050M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2022 Q3	2022 Q2	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$18.24K	$10.90K	$28.67K
YoY Change	590.91%	-67.63%	-86.35%
Cash & Equivalents	$18.24K	$10.90K	$21.81M
Short-Term Investments
Other Short-Term Assets	$14.88K	$29.75K	$0.00
YoY Change	-64.46%	-56.04%	-100.0%
Inventory
Prepaid Expenses	$14.88K	$29.75K
Receivables
Other Receivables
Total Short-Term Assets	$33.11K	$40.65K	$28.67K
YoY Change	-25.61%	-59.89%	-90.58%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$48.13M	$47.31M	$46.78M
YoY Change	3.59%	1.81%	0.69%
Other Assets	$220.00	$220.00	$220.00
YoY Change	0.0%	0.0%	-97.8%
Total Long-Term Assets	$48.14M	$47.31M	$46.78M
YoY Change	3.59%	1.81%	0.67%
TOTAL ASSETS
Total Short-Term Assets	$33.11K	$40.65K	$28.67K
Total Long-Term Assets	$48.14M	$47.31M	$46.78M
Total Assets	$48.17M	$47.35M	$46.81M
YoY Change	3.56%	1.67%	0.08%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable
YoY Change
Accrued Expenses	$76.06K	$73.56K	$71.06K
YoY Change	0.0%	136.83%	255.3%
Deferred Revenue
YoY Change
Short-Term Debt	$2.113M	$1.410M	$850.1K
YoY Change	805.42%	153170.65%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$2.189M	$1.484M	$921.1K
YoY Change	607.47%	4539.29%	5275.47%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$1.160M	$1.570M	$1.570M
YoY Change	-24.68%	1.95%	-79.34%
Total Long-Term Liabilities	$1.160M	$1.570M	$1.570M
YoY Change	-24.68%	1.95%	-79.34%
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.189M	$1.484M	$921.1K
Total Long-Term Liabilities	$1.160M	$1.570M	$1.570M
Total Liabilities	$3.349M	$3.054M	$2.491M
YoY Change	81.1%	94.25%	-67.3%
SHAREHOLDERS EQUITY
Retained Earnings	-$3.409M	-$3.014M
YoY Change
Common Stock	$1.450K	$1.450K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$3.316M	-$3.013M	-$2.462M
YoY Change
Total Liabilities & Shareholders Equity	$48.17M	$47.35M	$46.81M
YoY Change	3.56%	1.67%	0.08%

Cashflow Statement

Concept	2022 Q3	2022 Q2	2022 Q1
OPERATING ACTIVITIES
Net Income	$433.3K	-$23.60K	-$173.8K
YoY Change	-229.88%	-89.18%	60.46%
Depreciation, Depletion And Amortization		$4.470M	$343.4K
YoY Change
Cash From Operating Activities	-$82.66K	-$117.8K	-$173.4K
YoY Change	-68.26%	-32.37%	-12.64%
INVESTING ACTIVITIES
Capital Expenditures		$1.230M	$185.7K
YoY Change
Acquisitions
YoY Change
Other Investing Activities	-$1.380M	$0.00	$0.00
YoY Change	44705.19%	-100.0%	-100.0%
Cash From Investing Activities	-$1.380M	$0.00
YoY Change	44705.19%	-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	1.470M	100.0K	170.0K
YoY Change	532.26%	9900.0%	-99.64%
NET CHANGE
Cash From Operating Activities	-82.66K	-117.8K	-173.4K
Cash From Investing Activities	-1.380M	0.000
Cash From Financing Activities	1.470M	100.0K	170.0K
Net Change In Cash	7.340K	-17.77K	$0.00
YoY Change	-123.66%	-89.94%	-100.0%
FREE CASH FLOW
Cash From Operating Activities	-$82.66K	-$117.8K	-$173.4K
Capital Expenditures		$1.230M	$185.7K
Free Cash Flow		-$1.348M	-$359.2K
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	vena	Payment Of Offering Costs PaymentOfOfferingCosts		usd
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt		usd
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable		usd
	vena	Initial Classification Of Ordinary Shares Subject To Possible Redemption InitialClassificationOfOrdinarySharesSubjectToPossibleRedemption		usd
	vena	Allocation Of Offering Costs To Ordinary Shares Subject To Possible Redemption AllocationOfOfferingCostsToOrdinarySharesSubjectToPossibleRedemption		usd
	vena	Deferred Underwriting Fee Payable DeferredUnderwritingFeePayable		usd
	vena	Initial Recognition Of Warrant Liabilities InitialRecognitionOfWarrantLiabilities		usd
	vena	Proceeds Of Promissory Notes Deposited In Trust Account By Founder Shareholder ProceedsOfPromissoryNotesDepositedInTrustAccountByFounderShareholder		usd
	dei	Entity Central Index Key EntityCentralIndexKey	0001800392
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
CY2021Q4	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent		usd
CY2022Q2	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2021Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants		usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
	vena	Security Deposits SecurityDeposits		usd
	vena	Payments For Investment Of Cash In Trust Account PaymentsForInvestmentOfCashInTrustAccount		usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering		usd
	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement		usd
CY2021Q2	vena	Accretion Of Carrying Value To Redemption Value AccretionOfCarryingValueToRedemptionValue		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-06-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-40024
	dei	Entity Registrant Name EntityRegistrantName	VENUS ACQUISITION CORPORATION
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	E9
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	00-0000000
	dei	Entity Address Address Line1 EntityAddressAddressLine1	477 Madison Avenue
	dei	Entity Address Address Line2 EntityAddressAddressLine2	6th Floor
	dei	Entity Address City Or Town EntityAddressCityOrTown	New York
	dei	Entity Address State Or Province EntityAddressStateOrProvince	NY
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	10022
	dei	City Area Code CityAreaCode	(212)
	dei	Local Phone Number LocalPhoneNumber	786-7429
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Shell Company EntityShellCompany	true
CY2022Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	6050000	shares
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	10899	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	32090	usd
CY2022Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	29750	usd
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	16717	usd
CY2022Q2	us-gaap	Assets Current AssetsCurrent	40649	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	48807	usd
CY2022Q2	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	222	usd
CY2021Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	222	usd
CY2022Q2	us-gaap	Assets Held In Trust Noncurrent AssetsHeldInTrustNoncurrent	47306580	usd
CY2021Q4	us-gaap	Assets Held In Trust Noncurrent AssetsHeldInTrustNoncurrent	46469183	usd
CY2022Q2	us-gaap	Assets Assets	47347451	usd
CY2021Q4	us-gaap	Assets Assets	46518212	usd
CY2022Q2	us-gaap	Accounts Payable And Other Accrued Liabilities AccountsPayableAndOtherAccruedLiabilities	73558	usd
CY2021Q4	us-gaap	Accounts Payable And Other Accrued Liabilities AccountsPayableAndOtherAccruedLiabilities	93558	usd
CY2022Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	643421	usd
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	373421	usd
CY2022Q2	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	766665	usd
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	1483644	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	466979	usd
CY2022Q2	us-gaap	Shares Subject To Mandatory Redemption Settlement Terms Fair Value Of Shares SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares	420000	usd
CY2021Q4	us-gaap	Shares Subject To Mandatory Redemption Settlement Terms Fair Value Of Shares SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares	410000	usd
CY2022Q2	vena	Deferred Underwriting Compensation Noncurrent DeferredUnderwritingCompensationNoncurrent	1150000	usd
CY2021Q4	vena	Deferred Underwriting Compensation Noncurrent DeferredUnderwritingCompensationNoncurrent	1150000	usd
CY2022Q2	us-gaap	Liabilities Liabilities	3053644	usd
CY2021Q4	us-gaap	Liabilities Liabilities	2026979	usd
CY2022Q2	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	4600000	shares
CY2021Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	4600000	shares
CY2022Q2	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	10.28
CY2021Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	10.10
CY2022Q2	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	47306580	usd
CY2021Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	46469183	usd
CY2022Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2022Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1450000	shares
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1450000	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1450000	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1450000	shares
CY2022Q2	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	4600000	shares
CY2021Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	4600000	shares
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	1450	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	1450	usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-3014223	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1979400	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-3012773	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-1977950	usd
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	47347451	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	46518212	usd
CY2022Q2	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	90520	usd
CY2021Q2	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	218846	usd
	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	258158	usd
	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	297551	usd
CY2022Q2	us-gaap	Costs And Expenses CostsAndExpenses	90520	usd
CY2021Q2	us-gaap	Costs And Expenses CostsAndExpenses	218846	usd
	us-gaap	Costs And Expenses CostsAndExpenses	258158	usd
	us-gaap	Costs And Expenses CostsAndExpenses	297551	usd
CY2022Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	66917	usd
CY2021Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	706	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	70732	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	1088	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	10000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	10000	usd
CY2022Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	66917	usd
CY2021Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	706	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	60732	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-8912	usd
CY2022Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-23603	usd
CY2021Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-218140	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-197426	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-306463	usd
CY2022Q2	us-gaap	Profit Loss ProfitLoss	-23603	usd
CY2021Q2	us-gaap	Profit Loss ProfitLoss	-218140	usd
	us-gaap	Profit Loss ProfitLoss	-197426	usd
	us-gaap	Profit Loss ProfitLoss	-306463	usd
CY2022Q2	vena	Basic And Diluted Weighted Average Shares Outstanding Ordinary Shares Subject To Possible Redemption BasicAndDilutedWeightedAverageSharesOutstandingOrdinarySharesSubjectToPossibleRedemption	4600000	shares
CY2021Q2	vena	Basic And Diluted Weighted Average Shares Outstanding Ordinary Shares Subject To Possible Redemption BasicAndDilutedWeightedAverageSharesOutstandingOrdinarySharesSubjectToPossibleRedemption	4600000	shares
	vena	Basic And Diluted Weighted Average Shares Outstanding Ordinary Shares Subject To Possible Redemption BasicAndDilutedWeightedAverageSharesOutstandingOrdinarySharesSubjectToPossibleRedemption	4600000	shares
	vena	Basic And Diluted Weighted Average Shares Outstanding Ordinary Shares Subject To Possible Redemption BasicAndDilutedWeightedAverageSharesOutstandingOrdinarySharesSubjectToPossibleRedemption	3532597	shares
CY2022Q2	vena	Basic And Diluted Net Income Loss Per Ordinary Shares Subject To Possible Redemption BasicAndDilutedNetIncomeLossPerOrdinarySharesSubjectToPossibleRedemption	0.00
CY2021Q2	vena	Basic And Diluted Net Income Loss Per Ordinary Shares Subject To Possible Redemption BasicAndDilutedNetIncomeLossPerOrdinarySharesSubjectToPossibleRedemption	-0.04
	vena	Basic And Diluted Net Income Loss Per Ordinary Shares Subject To Possible Redemption BasicAndDilutedNetIncomeLossPerOrdinarySharesSubjectToPossibleRedemption	0.01
	vena	Basic And Diluted Net Income Loss Per Ordinary Shares Subject To Possible Redemption BasicAndDilutedNetIncomeLossPerOrdinarySharesSubjectToPossibleRedemption	0.23
CY2022Q2	vena	Basic And Diluted Weighted Average Shares Outstanding Ordinary Shares Attributable To Venus Acquisition Corporation BasicAndDilutedWeightedAverageSharesOutstandingOrdinarySharesAttributableToVenusAcquisitionCorporation	1450000	shares
CY2021Q2	vena	Basic And Diluted Weighted Average Shares Outstanding Ordinary Shares Attributable To Venus Acquisition Corporation BasicAndDilutedWeightedAverageSharesOutstandingOrdinarySharesAttributableToVenusAcquisitionCorporation	1450000	shares
	vena	Basic And Diluted Weighted Average Shares Outstanding Ordinary Shares Attributable To Venus Acquisition Corporation BasicAndDilutedWeightedAverageSharesOutstandingOrdinarySharesAttributableToVenusAcquisitionCorporation	1450000	shares
	vena	Basic And Diluted Weighted Average Shares Outstanding Ordinary Shares Attributable To Venus Acquisition Corporation BasicAndDilutedWeightedAverageSharesOutstandingOrdinarySharesAttributableToVenusAcquisitionCorporation	1380387	shares
CY2022Q2	vena	Basic And Diluted Net Income Loss Per Share Ordinary Shares Attributable To Venus Acquisition Corporation BasicAndDilutedNetIncomeLossPerShareOrdinarySharesAttributableToVenusAcquisitionCorporation	0.02
CY2021Q2	vena	Basic And Diluted Net Income Loss Per Share Ordinary Shares Attributable To Venus Acquisition Corporation BasicAndDilutedNetIncomeLossPerShareOrdinarySharesAttributableToVenusAcquisitionCorporation	-0.04
	vena	Basic And Diluted Net Income Loss Per Share Ordinary Shares Attributable To Venus Acquisition Corporation BasicAndDilutedNetIncomeLossPerShareOrdinarySharesAttributableToVenusAcquisitionCorporation	-0.17
	vena	Basic And Diluted Net Income Loss Per Share Ordinary Shares Attributable To Venus Acquisition Corporation BasicAndDilutedNetIncomeLossPerShareOrdinarySharesAttributableToVenusAcquisitionCorporation	-0.80
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	-2462254	usd
CY2022Q2	vena	Accretion Of Carrying Value To Redemption Value AccretionOfCarryingValueToRedemptionValue	-526916	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-23603	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-3012773	usd
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	-1244677	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-218140	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	-1462817	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-1977950	usd
	vena	Accretion Of Carrying Value To Redemption Value AccretionOfCarryingValueToRedemptionValue	-837397	usd
	us-gaap	Net Income Loss NetIncomeLoss	-197426	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-3012773	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-103662	usd
	vena	Sale Of Units In Initial Public Offering SaleOfUnitsInInitialPublicOffering	39960000	usd
	vena	Sale Of Ordinary Shares Value Founder In Private Placement SaleOfOrdinarySharesValueFounderInPrivatePlacement	1870000	usd
	vena	Sales Of Representative Shares SalesOfRepresentativeShares	75	usd
	vena	Offering Costs OfferingCosts	-2462767	usd
	vena	Initial Classification Of Ordinary Shares Subject To Possible Redemption Amount InitialClassificationOfOrdinarySharesSubjectToPossibleRedemptionAmount	-45249794	usd
	vena	Allocation Of Offering Costs To Common Stock Subject To Redemption AllocationOfOfferingCostsToCommonStockSubjectToRedemption	2422602	usd
	vena	Accretion Of Carrying Value To Redemption Value AccretionOfCarryingValueToRedemptionValue	-3632808	usd
	us-gaap	Net Income Loss NetIncomeLoss	-306463	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	-1462817	usd
	us-gaap	Profit Loss ProfitLoss	-197426	usd
	us-gaap	Profit Loss ProfitLoss	-306463	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	70732	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	1088	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	10000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	10000	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	13033	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	67683	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-20000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-8914	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-291191	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-374148	usd
	vena	Security Deposits SecurityDeposits	3081	usd
	vena	Payments For Investment Of Cash In Trust Account PaymentsForInvestmentOfCashInTrustAccount	46466500	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-46463419	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	75	usd
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	44875234	usd
	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	2250000	usd
	vena	Payment Of Offering Costs PaymentOfOfferingCosts	25830	usd
	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	270000	usd
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	228483	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	270000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	46870996	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-21191	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	33429	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	32090	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	239	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	10899	usd
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	33668	usd
	vena	Initial Classification Of Ordinary Shares Subject To Possible Redemption InitialClassificationOfOrdinarySharesSubjectToPossibleRedemption	45249794	usd
	vena	Allocation Of Offering Costs To Ordinary Shares Subject To Possible Redemption AllocationOfOfferingCostsToOrdinarySharesSubjectToPossibleRedemption	2422602	usd
	vena	Accretion Of Carrying Value To Redemption AccretionOfCarryingValueToRedemption	-837397	usd
	vena	Accretion Of Carrying Value To Redemption AccretionOfCarryingValueToRedemption	-3632808	usd
	vena	Deferred Underwriting Fee Payable DeferredUnderwritingFeePayable	1150000	usd
	vena	Initial Recognition Of Warrant Liabilities InitialRecognitionOfWarrantLiabilities	380000	usd
	vena	Proceeds Of Promissory Notes Deposited In Trust Account By Founder Shareholder ProceedsOfPromissoryNotesDepositedInTrustAccountByFounderShareholder	766665	usd
	us-gaap	Nature Of Operations NatureOfOperations	<p id="xdx_801_eus-gaap--NatureOfOperations_zxe3zNqAAyJa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 26.1pt; text-align: justify; text-indent: -26.1pt"><b>NOTE 1 – <span id="xdx_82C_zZUDMxYk4288">ORGANIZATION AND BUSINESS BACKGROUND</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Venus Acquisition Corporation (“Venus” or the “Company”) is a blank check company incorporated in the Cayman Islands on May 14, 2018. The Company was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses (“Business Combination”).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 10, 2021, the Company, VIYI Algorithm Inc., a Cayman Islands exempted company (“VIYI”), Venus Merger Sub Corp., a Cayman Islands exempted company and wholly-owned subsidiary of the Company (the “Merger Sub”) and WiMi Hologram Cloud Inc., a Cayman Islands company and the legal and beneficial owner of a majority of the issued and outstanding voting securities of VIYI (“Majority Shareholder”), entered into a Merger Agreement (the “Merger Agreement”). Venus Merger Sub Corp. is a company incorporated in the Cayman Islands for the purpose of effecting the Business Combination and to serve as the vehicle for, and be subsumed by, VIYI Algorithm Inc., pursuant to the terms of the Merger Agreement Merger Sub is wholly owned by Venus. See the further description below regarding the proposed business combination with VIYI.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is an early stage and an emerging growth company and, as such, the Company is subject to all of the risks associated with early stage and emerging growth companies.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All activities through June 30, 2022 relate to the Company’s formation, completion of its initial public offering (the “Initial Public Offering”) which occurred on February 11, 2021 and negotiation and consummation of the proposed Business Combination with VIYI. The Company will not generate any operating revenues until after the completion of a Business Combination, at the earliest. The Company generates non-operating income in the form of interest income from the proceeds derived from the Initial Public Offering, which proceeds are held in trust.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white"><b><i>Financing</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The registration statement for the Company’s Initial Public Offering became effective on February 8, 2021. On February 11, 2021, the Company consummated the Initial Public Offering of <span id="xdx_90B_ecustom--UnitsIssuedDuringPeriodSharesNewIssues_c20210111__20210211__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_pdd" title="Sale of Units, net of underwriting discounts (in shares)">4,600,000</span> units (the “Public Units”), which includes the full exercise by the underwriter of its over-allotment option in the amount of <span id="xdx_90C_ecustom--UnitsIssuedDuringPeriodSharesNewIssues_c20210111__20210211__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_pdd" title="Sale of Units, net of underwriting discounts (in shares)">600,000</span> Public Units, at $<span id="xdx_902_eus-gaap--SharesIssuedPricePerShare_c20210211__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_pdd" title="Purchase price, per unit">10.00</span> per Public Unit, generating gross proceeds of $<span id="xdx_905_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20210111__20210211__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_pp0p0" title="Sale of units in initial public offering aggragate amount">46,000,000</span> which is described in Note 3.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Simultaneously with the closing of the Initial Public Offering, the Company consummated the sale of, <span id="xdx_909_ecustom--UnitsIssuedDuringPeriodSharesNewIssues_c20210111__20210211__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_pdd" title="Sale of Units, net of underwriting discounts (in shares)">225,000</span> units (the “Private Units”) at a price of $<span id="xdx_909_eus-gaap--SharesIssuedPricePerShare_c20210211__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_pdd" title="Purchase price, per unit">10.00</span> per Private Unit in a private placement to Yolanda Management Corporation (the “Sponsor”), generating gross proceeds of $<span id="xdx_903_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20210111__20210211__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_pp0p0" title="Proceeds from Initial Public Offering">2,250,000</span>, which is described in Note 4.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Transaction costs amounted to $<span id="xdx_907_ecustom--TransactionCosts_c20220630__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_pp0p0" title="Transaction Costs">2,462,767</span>, consisting of $<span id="xdx_90F_ecustom--SaleOfStockUnderwritingFees_c20220630__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_pp0p0" title="Underwriting fees">805,000</span> of underwriting fees, $<span id="xdx_90A_ecustom--DeferredOfferingCostsNoncurrent_c20220630__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_pp0p0" title="Deferred underwriting fee payable">1,150,000</span> of deferred underwriting fees and $<span id="xdx_90B_ecustom--SaleOfStockOtherOfferingCosts_c20220630__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_pp0p0" title="Other offering costs">507,767</span> of other offering costs.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white"><b><i>Trust Account</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Following the closing of the Initial Public Offering on February 11, 2021, the aggregate amount of $<span id="xdx_902_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20210111__20210211__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_pp0p0" title="Proceeds from Initial Public Offering">46,460,000</span> ($<span id="xdx_90E_eus-gaap--SaleOfStockPricePerShare_c20210211__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_pdd" title="Price per share">10.10</span> per Public Unit) was placed in a trust account (the “Trust Account”) with Wilmington Trust, National Association acting as trustee. The funds held in the Trust Account can be invested in U.S. government securities, within the meaning set forth in Section 2(a)(16) of the Investment Company Act, with a maturity of 185 days or less, or in any open-ended investment company that holds itself out as a money market fund meeting certain conditions of Rule 2a-7 of the Investment Company Act, as determined by the Company, until the earlier of: (i) the completion of a Business Combination and (ii) the distribution of the funds in the Trust Account to the Company’s shareholders, as described below, except that interest earned on the Trust Account can be released to the Company to pay its tax obligations. At closing of the Initial Public Offering, the sum of $<span id="xdx_90F_ecustom--WorkingCapitalFunds_c20210211__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_pp0p0" title="Working Capital funds">418,430</span> was released to the Company to fund its working capital needs.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white"><b><i>Business Combination</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company’s management has broad discretion with respect to the specific application of the net proceeds of the Initial Public Offering and sale of the Private Units, although substantially all of the net proceeds are held in trust and are intended to be applied generally toward consummating a Business Combination. NASDAQ rules provide that the Business Combination must be with one or more target businesses that together have a fair market value equal to at least <span id="xdx_90F_ecustom--PercentageOfAssetHeldInTrustAccount_dp_c20220101__20220630_z74GxNIsLBRd" title="Percentage of asset held in trust account">80%</span> of the balance in the Trust Account (as defined below) (less any deferred underwriting commissions and taxes payable on interest earned) at the time of the signing of an agreement to enter into a Business Combination. The Company will only complete a Business Combination if the post-Business Combination company owns or acquires <span id="xdx_909_ecustom--BusinessCombinationPercentageOfVotingSecurities_iI_dp_c20220630_zrkXy27QRsKa" title="Business combination, percentage of voting securities">50%</span> or more of the outstanding voting securities of the target or otherwise acquires a controlling interest in the target sufficient for it not to be required to register as an investment company under the Investment Company Act of 1940, as amended (the “Investment Company Act”). There is no assurance that the Company will be able to successfully effect a Business Combination.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company will provide its shareholders with the opportunity to redeem all or a portion of their Public Shares upon the completion of a Business Combination either (i) in connection with a shareholder meeting called to approve the Business Combination or (ii) by means of a tender offer. In connection with an Initial Business Combination, the Company may seek shareholder approval of a Business Combination at a meeting called for such purpose at which shareholders may seek to redeem their shares, regardless of whether they vote for or against a Business Combination. The Company will proceed with a Business Combination only if the Company has net tangible assets of at least $<span id="xdx_903_eus-gaap--BusinessCombinationContingentConsiderationAsset_c20220630_pp0p0" title="Business Combination, minimum amount of net tangible assets">5,000,001</span> upon such consummation of a Business Combination and, if the Company seeks shareholder approval, a majority of the outstanding shares voted are voted in favor of the Business Combination.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Notwithstanding the foregoing, if the Company seeks shareholder approval of a Business Combination and it does not conduct redemptions pursuant to the tender offer rules, the Company’s amended and restated memorandum and articles of association provides that a public shareholder, together with any affiliate of such shareholder or any other person with whom such shareholder is acting in concert or as a “group” (as defined under Section 13 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), will be restricted from seeking redemption rights with respect to 15% or more of the Public Shares without the Company’s prior written consent.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If a shareholder vote is not required and the Company does not decide to hold a shareholder vote for business or other legal reasons, the Company will, pursuant to its amended and restated memorandum and articles of association, offer such redemption pursuant to the tender offer rules of the Securities and Exchange Commission (“SEC”), and file tender offer documents containing substantially the same information as would be included in a proxy statement with the SEC prior to completing a Business Combination.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The shareholders will be entitled to redeem their Public Shares for a pro rata portion of the amount then in the Trust Account (initially $<span title="Purchase price, per unit">10.10</span> per Public Share, subject to increase of up to an additional $<span id="xdx_90A_ecustom--AggregateProceedsHeldInTrustAccountPerPublicShare_c20220101__20220630_pdd" title="Per public share">0.30</span> per Public Share in the event that the Sponsor elects to extend the period of time to consummate a Business Combination (see below), plus any pro rata interest earned on the funds held in the Trust Account and not previously released to the Company to pay its tax obligations). The per-share amount to be distributed to shareholders who redeem their Public Shares will not be reduced by the deferred underwriting commissions the Company will pay to the underwriter (as discussed in Note 6). There will be no redemption rights upon the completion of a Business Combination with respect to the Company’s rights or warrants. The ordinary shares will be recorded at redemption value and classified as temporary equity upon the completion of the Initial Public Offering, in accordance with Accounting Standards Codification (“ASC”) Topic 480 “Distinguishing Liabilities from Equity” (“ASC 480”).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Sponsor and any of the Company’s officers or directors that may hold Founder Shares (as defined in Note 6) (the “shareholders”) and the underwriters will agree (a) to vote their Founder Shares, the ordinary shares included in the Private Units (the “Private Shares”) and any Public Shares purchased during or after the Initial Public Offering in favor of a Business Combination, (b) not to propose an amendment to the Company’s amended and restated memorandum and articles of association with respect to the Company’s pre-Business Combination activities prior to the consummation of a Business Combination unless the Company provides dissenting public shareholders with the opportunity to redeem their Public Shares in conjunction with any such amendment; (c) not to redeem any shares (including the Founder Shares) and Private Shares into the right to receive cash from the Trust Account in connection with a shareholder vote to approve a Business Combination (or to sell any shares in a tender offer in connection with a Business Combination if the Company does not seek shareholder approval in connection therewith) or a vote to amend the provisions of the amended and restated Memorandum and Articles of Association relating to shareholders’ rights of pre-Business Combination activity and (d) that the Founder Shares and Private Shares shall not participate in any liquidating distributions upon winding up if a Business Combination is not consummated. However, the shareholders will be entitled to liquidating distributions from the Trust Account with respect to any Public Shares purchased during or after the Initial Public Offering if the Company fails to complete its Business Combination.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 10, 2021, the Company entered into the Merger Agreement, which provides for a Business Combination between Venus and VIYI Algorithm Inc. Pursuant to the Merger Agreement, the Business Combination will be effected as a stock transaction and is intended to be qualified as a tax-free reorganization. The Merger Agreement is by and among Venus, Merger Sub, VIYI, and WiMi Hologram Cloud Inc, a Cayman Islands limited liability company as the representative of VIYI’s shareholders. The aggregate consideration for the Acquisition Merger is $<span id="xdx_904_eus-gaap--PaymentsToAcquireBusinessesNetOfCashAcquired_pp0p0_c20210601__20210610__us-gaap--StatementEquityComponentsAxis__custom--MergerSubCommonStockMember_z1QO6GF5MuD8" title="Aggregate of acquisition amount">400,000,000</span>, payable in the form of <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210601__20210610__us-gaap--StatementEquityComponentsAxis__custom--MergerSubCommonStockMember_zRkzPl7jHdfe" title="Aggregate of shares">39,600,000</span> newly issued ordinary shares of Merger Sub (“Merger Sub Ordinary Share”) valued at $<span id="xdx_900_eus-gaap--SaleOfStockPricePerShare_iI_c20210610__us-gaap--StatementEquityComponentsAxis__custom--MergerSubCommonStockMember_zMT4hWBSxxMg" title="Price per share">10.10</span> per share.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Upon the closing of the Business Combination, the former Venus shareholders will receive the consideration specified below and the former VIYI shareholders will receive an aggregate of <span id="xdx_909_eus-gaap--SharesIssued_iI_c20210610__us-gaap--StatementEquityComponentsAxis__custom--MergerSubCommonStockMember_zGBIYqsHCk4a" title="Issuance of shares">39,600,000</span> shares of Merger Sub Ordinary Share.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company will be seeking approval from its shareholders of the proposed Business Combination and Merger with VIYI. The Company has filed a Preliminary Proxy Statement on Schedule 14A with the SEC regarding the terms and conditions of the proposed Merger with VIYI and other matters. The Preliminary Proxy Statement is under review by the SEC. Assuming SEC finishes the review of the Proxy Statement, of which there can be no assurance, the Company will provide its shareholders with definitive materials to consider in connection with the solicitation for approval of the Merger with VIYI and other matters as described in the Proxy Statement.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 11, 2022, March 11, 2022, April 11, 2022, May 11, 2022, June 11, 2022, July 11, 2022 and August 11, 2022, the Company issued an unsecured promissory note, each in an amount of $<span id="xdx_90D_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20220211__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember_zPRPLykX4Duh" title="Note amount"><span id="xdx_90D_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20220311__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember_zOoXuxvgyJY1" title="Note amount"><span id="xdx_90C_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20220411__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember_zMu55mmZrSbg" title="Note amount"><span id="xdx_90E_eus-gaap--DebtInstrumentFaceAmount_c20220511__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember_pp0p0" title="Note amount"><span id="xdx_908_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20220611__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember_zAVzQcvTbYH4" title="Note amount"><span id="xdx_906_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20220711__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember_zlyN9abgKtS7" title="Note amount"><span id="xdx_900_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20220811__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember_z7r6Lrb9VEE8" title="Note amount">153,333</span></span></span></span></span></span></span> to the Sponsor, pursuant to which such amount had been deposited into the Trust Account in order to extend the amount of available time to complete a business combination until September 11, 2022. However, if the Company anticipates that it may not be able to consummate a Business Combination within 12 months (including the proposed Business combination with VIYI), the Company may extend the period of time to consummate a Business Combination up to nine times, each by an additional month (for a total of 21 months to complete a Business Combination (the “Combination Period”). In order to extend the time available for the Company to consummate a Business Combination, the Sponsor or its affiliate or designees must deposit into the Trust Account $<span id="xdx_906_ecustom--InvestmentOfProceedsInTrustAccount_c20220101__20220630_pp0p0">153,333 </span>(approximately $<span id="xdx_90B_ecustom--InvestmentOfProceedsInTrustAccountPerShares_c20220101__20220630_pdd">0.033 </span>per Public Share), up to an aggregate of $<span id="xdx_90E_ecustom--AggregateProceedsHeldInTrustAccount_c20220101__20220630_pp0p0">1,380,000</span>, or $<span id="xdx_909_ecustom--AggregateProceedsHeldInTrustAccountPerPublicShare_c20220101__20220630_zc229S9ublxc">0.30 </span>per Public Share, on or prior to the date of the applicable deadline, for each one month extension. Any funds which may be provided to extend the time frame will be in the form of a loan to us from our sponsor. For the extensions that we have made, the loans are interest free and will not be repaid unless and until we complete a business combination. For the extensions that may be made in the future, the final and definitive terms of the loan in connection with any such loans have not yet been negotiated, but any such loan would be interest free and not repaid unless and until we complete a business combination.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of the date of these unaudited condensed consolidated financial statements, the Company has extended the period of time to consummate a business combination six times by an additional one month each time (for a total of up to 6 months from the consummation of the Public Offering to complete a business combination). The insiders have received non-interest bearing, unsecured promissory notes equal to the amount of any such deposits (i.e., $153,333 for each of the six extensions since February 2022). Such notes would either be paid upon consummation of its initial business combination, or, at the lender’s discretion, converted upon consummation of its business combination into additional Private Units at a price of $10.00 per unit.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On each of February 11, 2022, March 11, 2022, April 11, 2022, May 11, 2022, June 11, 2022, July 11, 2022 and August 11, 2022, the Company issued an unsecured promissory note in an amount of $<span id="xdx_90D_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20220211__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember_zIKg3ghpTSB5" title="Note amount"><span id="xdx_903_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20220311__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember_zUpYZyVbXck2" title="Note amount"><span id="xdx_90A_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20220411__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember_zVfpRRm2bBG4" title="Note amount"><span id="xdx_905_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20220511__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember_zu4c2vGoeHQ7" title="Note amount"><span id="xdx_90D_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20220611__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember_zw02kcV3DfH1" title="Note amount"><span id="xdx_905_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20220711__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember_zxSdlfI719C7" title="Note amount"><span id="xdx_90D_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20220811__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SponsorMember_z7ZcWnUM92nk">153,333</span></span></span></span></span></span></span> to the sponsor, pursuant to which such amount had been deposited into the Trust Account in order to extend the amount of available time to complete a business combination until September 11, 2022. Company has two more times to extend the amount of available time to complete a business combination until October 11, 2022. As of June 30, 2022 and December 31, 2021, the note payable balance of $<span id="xdx_90A_eus-gaap--NotesPayable_c20220630_pp0p0" title="Note payable">766,665</span> and $<span id="xdx_90D_eus-gaap--NotesPayable_c20211231_pp0p0" title="Note payable">0</span>, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the Company is unable to complete a Business Combination within the Combination Period, the Company will (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but no more than ten business days thereafter, redeem 100% of the outstanding Public Shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest earned (net of taxes payable and less interest to pay dissolution expenses up to $50,000), divided by the number of then outstanding Public Shares, which redemption will completely extinguish public shareholders’ rights as shareholders (including the right to receive further liquidation distributions, if any), subject to applicable law, and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the remaining shareholders and the Company’s board of directors, proceed to commence a voluntary liquidation and thereby a formal dissolution of the Company, subject in each case to its obligations to provide for claims of creditors and the requirements of applicable law. The underwriter has agreed to waive its rights to the deferred underwriting commission held in the Trust Account in the event the Company does not complete a Business Combination within the Combination Period and, in such event, such amounts will be included with the funds held in the Trust Account that will be available to fund the redemption of the Public Shares. In the event of such distribution, it is possible that the per share value of the assets remaining available for distribution will be less than the Initial Public Offering price per Unit ($10.00).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Sponsor has agreed that it will be liable to the Company, if and to the extent any claims by a vendor for services rendered or products sold to the Company, or a prospective target business with which the Company has discussed entering into a transaction agreement, reduce the amounts in the Trust Account to below (i) $10.10 per share or (ii) such lesser amount per Public Share held in the Trust Account as of the date of the liquidation of the Trust Account due to reductions in the value of the trust assets, except as to any claims by a third party who executed a waiver of any and all rights to seek access to the Trust Account and except as to any claims under the Company’s indemnity of the underwriters of the Initial Public Offering against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the “Securities Act”). In the event that an executed waiver is deemed to be unenforceable against a third party, the Sponsor will not be responsible to the extent of any liability for such third-party claims. The Company will seek to reduce the possibility that the Sponsor will have to indemnify the Trust Account due to claims of creditors by endeavoring to have all vendors, service providers, prospective target businesses or other entities with which the Company does business, execute agreements with the Company waiving any right, title, interest or claim of any kind in or to monies held in the Trust Account.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white"><b><i>Liquidity and going concern</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company initially had 12 months from the consummation of this offering to consummate the initial business combination. If the Company does not complete a business combination within 12 months from the consummation of the Public Offering, the Company will trigger an automatic winding up, dissolution and liquidation pursuant to the terms of the amended and restated memorandum and articles of association. As a result, this has the same effect as if the Company had formally gone through a voluntary liquidation procedure under the Companies Law. Accordingly, no vote would be required from our shareholders to commence such a voluntary winding up, dissolution and liquidation. However, the Company may extend the period of time to consummate a business combination nine times (for a total of up to 21 months from the consummation of the Public Offering to complete a business combination). As of the date of this report, the Company has extended six times by an additional one month each time (for a total of up to 18 months from the consummation of the Public Offering to complete a business combination), and so it now has until September 11, 2022 to consummate a business combination. Pursuant to the terms of the current amended and restated memorandum and articles of association and the trust agreement between the Company and Wilmington Trust, National Association, in order to extend the time available for the Company to consummate our initial business combination, the Company’s insiders or their affiliates or designees, upon five days advance notice prior to the applicable deadline, must deposit into the Trust Account $0.033 per public share, on or prior to the date of the applicable deadline. The insiders have received non-interest bearing, unsecured promissory notes equal to the amount of any such deposits (i.e., $153,333 for each of the extensions since February 2022) that will not be repaid in the event that we are unable to close a business combination unless there are funds available outside the Trust Account to do so. Such notes would either be paid upon consummation of the Company’s initial business combination, or, at the lender’s discretion, converted upon consummation of our business combination into additional Private Units at a price of $10.00 per unit. The Company’s shareholders have approved the issuance of the Private Units upon conversion of such notes, to the extent the holder wishes to so convert such notes at the time of the consummation of the Company’s initial business combination. In the event that the Company receives notice from the Company’s insiders five days prior to the applicable deadline of their intent to effect an extension, the Company intends to issue a press release announcing such intention at least three days prior to the applicable deadline. In addition, the Company intends to issue a press release the day after the applicable deadline announcing whether or not the funds had been timely deposited. If the Company is unable to consummate the Company’s initial business combination by September 11, 2022 (unless further extended), the Company will, as promptly as possible but not more than ten business days thereafter, redeem 100% of the Company’s outstanding public shares for a pro rata portion of the funds held in the Trust Account, including a pro rata portion of any interest earned on the funds held in the Trust Account and not necessary to pay taxes, and then seek to liquidate and dissolve. However, the Company may not be able to distribute such amounts as a result of claims of creditors which may take priority over the claims of the Company’s public shareholders. In the event of dissolution and liquidation, the public rights will expire and will be worthless.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">Accordingly, the Company may not be able to obtain additional financing. If the Company is unable to raise additional capital, it may be required to take additional measures to conserve liquidity, which could include, but not necessarily be limited to, curtailing operations, suspending the pursuit of a potential transaction, and reducing overhead expenses. The Company cannot provide any assurance that new financing will be available to it on commercially acceptable terms, if at all. These conditions raise substantial doubt about the Company’s ability to continue as a going concern if a business combination is not consummated by September 11, 2022 (unless further extended). These unaudited condensed consolidated financial statements do not include any adjustments relating to the recovery of the recorded assets or the classification of the liabilities that might be necessary should the Company be unable to continue as a going concern.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/>
	vena	Percentage Of Asset Held In Trust Account PercentageOfAssetHeldInTrustAccount	0.80	pure
CY2022Q2	vena	Business Combination Percentage Of Voting Securities BusinessCombinationPercentageOfVotingSecurities	0.50	pure
CY2022Q2	us-gaap	Business Combination Contingent Consideration Asset BusinessCombinationContingentConsiderationAsset	5000001	usd
	vena	Aggregate Proceeds Held In Trust Account Per Public Share AggregateProceedsHeldInTrustAccountPerPublicShare	0.30
	vena	Investment Of Proceeds In Trust Account InvestmentOfProceedsInTrustAccount	153333	usd
	vena	Investment Of Proceeds In Trust Account Per Shares InvestmentOfProceedsInTrustAccountPerShares	0.033
	vena	Aggregate Proceeds Held In Trust Account AggregateProceedsHeldInTrustAccount	1380000	usd
	vena	Aggregate Proceeds Held In Trust Account Per Public Share AggregateProceedsHeldInTrustAccountPerPublicShare	0.30
CY2022Q2	us-gaap	Notes Payable NotesPayable	766665	usd
CY2021Q4	us-gaap	Notes Payable NotesPayable	0	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_846_eus-gaap--UseOfEstimates_zBZTSW21ZJcl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span id="xdx_86F_zcqxZlQY2PEb">Use of Estimates</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of income and expenses during the reporting period.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the unaudited condensed consolidated financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2022Q2	us-gaap	Cash Cash	0	usd
CY2021Q4	us-gaap	Cash Cash	0	usd
	us-gaap	Gross Profit GrossProfit	-197426	usd
	us-gaap	Gross Profit GrossProfit	-306463	usd
	vena	Accretion Of Carrying Value To Redemption Value AccretionOfCarryingValueToRedemptionValue	-837397	usd
CY2022Q2	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	4600000	shares
CY2021Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	4600000	shares
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_842_eus-gaap--ConcentrationRiskCreditRisk_zBc5FI10JGM8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span id="xdx_869_zu0FQ3ygJXoe">Concentration of Credit Risk</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial instruments that potentially subject the Company to concentration of credit risk consist of cash and trust accounts in a financial institution which, at times may exceed the Federal depository insurance coverage of $<span id="xdx_900_eus-gaap--CashFDICInsuredAmount_c20220630_pp0p0" title="FDIC limit">250,000</span>. The Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2022Q2	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
CY2022Q2	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2022Q2	us-gaap	Income Tax Examination Penalties And Interest Accrued IncomeTaxExaminationPenaltiesAndInterestAccrued	0	usd
CY2021Q4	us-gaap	Income Tax Examination Penalties And Interest Accrued IncomeTaxExaminationPenaltiesAndInterestAccrued	0	usd
CY2022Q2	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2412500	shares
	vena	Accretion Of Carrying Value To Redemption Value AccretionOfCarryingValueToRedemptionValue	-3632808	usd
	vena	Net Loss NetLoss	-1034823	usd
	vena	Net Loss NetLoss	-3939271	usd
CY2022Q2	us-gaap	Gross Profit GrossProfit	-23603	usd
CY2021Q2	us-gaap	Gross Profit GrossProfit	-218140	usd
CY2022Q2	vena	Accretion Of Carrying Value To Redemption Value AccretionOfCarryingValueToRedemptionValue	-526916	usd
CY2022Q2	vena	Net Loss NetLoss	-550519	usd
CY2021Q2	vena	Net Loss NetLoss	-218140	usd
CY2022Q2	us-gaap	Cash Cash	0	usd
CY2021Q4	us-gaap	Cash Cash	0	usd
CY2022Q2	us-gaap	Notes Payable Current NotesPayableCurrent	643421	usd
CY2021Q4	us-gaap	Notes Payable Current NotesPayableCurrent	373421	usd
	vena	Investment Of Proceeds In Trust Account InvestmentOfProceedsInTrustAccount	153333	usd
	vena	Investment Of Proceeds In Trust Account Per Shares InvestmentOfProceedsInTrustAccountPerShares	0.033
	vena	Aggregate Proceeds Held In Trust Account AggregateProceedsHeldInTrustAccount	1380000	usd
	vena	Aggregate Proceeds Held In Trust Account Per Public Share AggregateProceedsHeldInTrustAccountPerPublicShare	0.30
CY2022Q2	vena	Related Party Extension Loans RelatedPartyExtensionLoans	766665	usd
CY2021Q4	vena	Related Party Extension Loans RelatedPartyExtensionLoans	0	usd
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
	us-gaap	Common Stock Voting Rights CommonStockVotingRights	Holders of the ordinary shares are entitled to one vote for each ordinary share.
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1450000	shares
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1450000	shares
CY2022Q2	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	4600000	shares
	vena	Warrant Exercise Price WarrantExercisePrice	11.50
CY2022Q2	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	420000	usd
CY2021Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	410000	usd
	us-gaap	Payments For Rent PaymentsForRent	901	usd
	us-gaap	Payments For Rent PaymentsForRent	6109	usd
	vena	Percentage Of Deferred Underwriting Fees PercentageOfDeferredUnderwritingFees	0.025	pure
	vena	Deferred Underwriting Fees DeferredUnderwritingFees	1150000	usd
CY2022Q2	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	4600000	shares

Files In Submission

Name	View Source	Status
0001829126-22-015804-index-headers.html	Edgar Link	pending
0001829126-22-015804-index.html	Edgar Link	pending
0001829126-22-015804.txt	Edgar Link	pending
0001829126-22-015804-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
vena-20220630.xsd	Edgar Link	pending
venusacquisition_10q.htm	Edgar Link	pending
venusacquisition_ex31-1.htm	Edgar Link	pending
venusacquisition_ex31-2.htm	Edgar Link	pending
venusacquisition_ex32-1.htm	Edgar Link	pending
vena-20220630_cal.xml	Edgar Link	unprocessable
vena-20220630_def.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
vena-20220630_pre.xml	Edgar Link	unprocessable
venusacquisition_10q_htm.xml	Edgar Link	completed
venusacquisition_ex32-2.htm	Edgar Link	pending
vena-20220630_lab.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$MLGO
MicroAlgo Inc. Stock $mlgo

2022 Q3 Form 10-Q Financial Statement

#000182912622015804 Filed on August 15, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MLGO MicroAlgo Inc. Stock $mlgo

2022 Q3 Form 10-Q Financial Statement

#000182912622015804 Filed on August 15, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MLGO
MicroAlgo Inc. Stock $mlgo